Matthew Czarny, MD
Interventional Cardiology · Baltimore, MDNPI 1073759866
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 79.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $11,450 and has fallen 86.7% since, to $1,524 in 2025.
Across 76 payments — averaging $193.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Abbott$2K
- Edwards Lifesciences$253
- Shockwave Medical, Inc$143
- Boston Scientific$113
- Irhythm Technologies, Inc.$37
- plus $96 from 4 others
Across 11 payments — averaging $3455.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$28K
- Abbott$6K
- Medtronic$4K
What the payments were for
- Speaking & faculty fees$8,19456%
- Travel & lodging$3,56824%
- Food & beverage$2,91120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 41 | $11,705 |
| Abbott | 24 | $2,326 |
| Edwards Lifesciences | 2 | $253 |
| Shockwave Medical, Inc | 1 | $143 |
| Boston Scientific | 1 | $113 |
| Irhythm Technologies, Inc. | 2 | $37 |
| Terumo Medical Corporation | 2 | $35 |
| Biosense Webster, Inc. | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,672 in reported general payments places this provider in the 60th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 21 | $28,655 |
| JardianceEmpagliflozin | 15 | $18,936 |
| EliquisApixaban | 11 | $14,154 |
| Metoprolol Succinate | 44 | $1,020 |
| Ezetimibe | 11 | $995 |
| Losartan Potassium | 15 | $435 |
| Amlodipine Besylate | 19 | $412 |
| Atorvastatin Calcium | 21 | $384 |
| Furosemide | 36 | $240 |
| Carvedilol | 21 | $83 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Baltimore
- Aloke FinnBaltimore$575K
- John WangBaltimore$138K
- Diljon ChahalBaltimore$78K
- Jon ResarBaltimore$40K
- Faisal RahmanBaltimore$36K
- Matthew VossBaltimore$33K
- Hooman BakhshiBaltimore$32K
- Daniel AmbinderBaltimore$32K
- Rani HasanBaltimore$22K
- Ajar KocharBaltimore$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.